Filtered By:
Condition: Brain Tumor
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 151 results found since Jan 2013.
A H3K27M-targeted vaccine in adults with diffuse midline glioma
Nat Med. 2023 Sep 21. doi: 10.1038/s41591-023-02555-6. Online ahead of print.ABSTRACTSubstitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M+ tumors in major histocompatibility complex-humanized mice. Here we describe a first-in-human treatment with H3K27M-vac of eight adult patients with progressive H3K27M+ diffuse midline glioma on a compassionate use basis. Five patients received H3K27M-vac combined with anti-PD-1 treat...
Source: Cancer Control - September 22, 2023 Category: Cancer & Oncology Authors: Niklas Grassl Isabel Poschke Katharina Lindner Lukas Bunse Iris Mildenberger Tamara Boschert Kristine J ähne Edward W Green Ingrid H ülsmeyer Simone J ünger Tobias Kessler Abigail K Suwala Philipp Eisele Michael O Breckwoldt Peter Vajkoczy Oliver M Gra Source Type: research
NLGN4X TCR transgenic T cells to treat gliomas
CONCLUSION: NLGN4X-TCR-T demonstrates efficacy in a preclinical glioblastoma model. On a global scale, we provide first evidence for the therapeutic retrieval of vaccine-induced human TCRs for the off-the-shelf treatment of glioblastoma patients.PMID:37715782 | DOI:10.1093/neuonc/noad172
Source: Cancer Control - September 16, 2023 Category: Cancer & Oncology Authors: C Kr ämer M Kilian Y C Chih A Kourtesakis D C Hoffmann T Boschert P Koopmann K Sanghvi A De Roia S Jung K J ähne B Day L D Shultz M Ratliff R Harbottle E W Green R Will W Wick M Platten L Bunse Source Type: research
The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer
Conclusion: These results show that VC2 therapy can improve anti-tumor response associated with a better control of tumor metastasis. improve T cell responses and reduce pro-tumor biomarker gene transcription. VC2 holds promise for further development as an oncolytic and immunotherapeutic approach to treat breast and other cancers.PMID:37388243 | PMC:PMC10303929 | DOI:10.3389/fmolb.2023.1199068
Source: Herpes - June 30, 2023 Category: Infectious Diseases Authors: Rafiq Nabi Farhana Musarrat Jose Cesar Menk P Lima Ingeborg M Langohr Vladimir N Chouljenko Konstantin G Kousoulas Source Type: research
Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trials
Neurooncol Adv. 2023 May 10;5(1):vdad053. doi: 10.1093/noajnl/vdad053. eCollection 2023 Jan-Dec.ABSTRACTIsocitrate dehydrogenase (IDH) is a key enzyme in normal metabolism and homeostasis. However, mutant forms of IDH are also defining features of a subset of diffuse gliomas. In this review, we highlight current techniques targeting IDH-mutated gliomas and summarize current and completed clinical trials exploring these strategies. We discuss clinical data from peptide vaccines, mutant IDH (mIDH) inhibitors, and PARP inhibitors. Peptide vaccines have the unique advantage of targeting the specific epitope of a patient's tumo...
Source: Adv Data - June 8, 2023 Category: Epidemiology Authors: Nikhil Sharma Arka N Mallela Diana D Shi Lilly W Tang Hussam Abou-Al-Shaar Zachary C Gersey Xiaoran Zhang Samuel K McBrayer Kalil G Abdullah Source Type: research
Uncovering transcriptomic landscape alterations of CAN-2409 in < em > in vitro < /em > and < em > in vivo < /em > glioma models
CONCLUSION: CAN-2409 significantly alters the transcriptome both in vitro and in vivo. Comparison of pathway enrichment revealed mutual and differential utilization of pathways under both conditions, suggesting a modulating influence on the cell cycle in tumor cells, and of the tumor microenvironment on the transcriptome in vivo. IL-12 synthesis likely depends on interactions with the tumor microenvironment, and it facilitates CAN-2409 cell killing. This dataset provides potential to understand resistance mechanisms and identify potential biomarkers for future studies.PMID:37228396 | PMC:PMC10203593 | DOI:10.3389/fmed.2023.1140352
Source: Cancer Control - May 25, 2023 Category: Cancer & Oncology Authors: Marilin S Koch Mykola Zdioruk Michal O Nowicki Michael S Hoetker Zachary T Herbert Francesca Barone Paul P Tak E Antonio Chiocca Ghazaleh Tabatabai Sean E Lawler Source Type: research
Digging the intercellular crosstalk via extracellular vesicles: May exosomes be the drug delivery solution for target glioblastoma?
J Control Release. 2023 Apr 27:S0168-3659(23)00288-2. doi: 10.1016/j.jconrel.2023.04.038. Online ahead of print.ABSTRACTGlioblastoma (GBM) is an adult's most aggressive brain tumor. The advances in molecular pathology and cell signaling pathways have deepened researchers' understanding of intercellular communication mechanisms that can induce tumor progression, namely the release of extracellular vesicles. Exosomes are small extracellular vesicles in various biological fluids released by almost all cells, thus carrying various biomolecules specific to their parental cell. Several pieces of evidence indicate that exosomes m...
Source: Cancer Control - April 29, 2023 Category: Cancer & Oncology Authors: Ana Macedo-Pereira Cl áudia Martins Jorge Lima Bruno Sarmento Source Type: research
Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity
In this study, we investigated the safety of a live attenuated Japanese encephalitis vaccine strain (JEV-LAV) virus as an oncolytic virus for intracerebral injection in mice. We infected different GBM cell lines with JEV-LAV to investigate whether it had growth inhibitory effects on GBM cell lines in vitro. We used two models for evaluating the effect of JEV-LAV on GBM growth in mice. We investigated the antitumor immune mechanism of JEV-LAV through flow cytometry and immunohistochemistry. We explored the possibility of combining JEV-LAV with PD-L1 blocking therapy. This work suggested that JEV-LAV had oncolytic activity a...
Source: Cancer Control - April 28, 2023 Category: Cancer & Oncology Authors: Zhongbing Qi Jing Zhao Yuhua Li Bin Zhang Shichuan Hu Yanwei Chen Jinhu Ma Yongheng Shu Yunmeng Wang Ping Cheng Source Type: research
A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy
CONCLUSION: rMVA-IL13Rα2 virus can successfully infect mammalian cells to express IL-13Rα2 in a biologically active form on the surface of infected cells. To evaluate the efficacy of rMVA-IL13Rα2, immunization studies are planned in murine tumor models.PMID:36999709 | DOI:10.2174/1566524023666230331085007
Source: Cancer Control - March 31, 2023 Category: Cancer & Oncology Authors: Yuki Sato Ramjay Vatsan Bharat H Joshi Syed R Husain Raj K Puri Source Type: research
